Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Molindone Hydrochloride

FDA-approved product (capsule, oral), marketed as Moban, Molindone Hydrochloride.

Registered studies
8
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Molindone Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Psychosis
  • Schizophrenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Indole derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA36.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli33.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

8registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Molindone Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Molindone Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group

    NCT04002700 · start 2019-05-06

    Registered record
    Registry ID
    NCT04002700
    Conditions
    Stroke
    Interventions
    Haloperidol; Typical Antipsychotics; Atypical Antipsychotics
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-05-06
    Completion
    2019-05-31
    Enrolment
    1,234,412

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStroke
    InterventionHaloperidol; Typical Antipsychotics; Atypical Antipsychotics
    PhaseNot recorded
    Registry statusCompleted

  • Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)

    NCT02691182 · start 2016-04

    Registered record
    Registry ID
    NCT02691182
    Conditions
    Attention Deficit Hyperactivity Disorder (ADHD)
    Interventions
    SPN-810
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2016-04
    Completion
    2021-05
    Enrolment
    491

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAttention Deficit Hyperactivity Disorder (ADHD)
    InterventionSPN-810
    PhasePhase 3
    Registry statusTerminated

  • Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)

    NCT02618434 · start 2016-02-16

    Registered record
    Registry ID
    NCT02618434
    Conditions
    Attention Deficit Hyperactivity Disorder (ADHD)
    Interventions
    SPN-810 (18 mg); SPN-810 (36 mg); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-02-16
    Completion
    2020-02-14
    Enrolment
    297

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAttention Deficit Hyperactivity Disorder (ADHD)
    InterventionSPN-810 (18 mg); SPN-810 (36 mg); Placebo
    PhasePhase 3
    Registry statusCompleted

  • Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)

    NCT02618408 · start 2016-01-25

    Registered record
    Registry ID
    NCT02618408
    Conditions
    Attention Deficit Hyperactivity Disorder (ADHD)
    Interventions
    SPN-810 (18 mg); SPN-810 (36 mg); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-01-25
    Completion
    2019-10-24
    Enrolment
    333

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAttention Deficit Hyperactivity Disorder (ADHD)
    InterventionSPN-810 (18 mg); SPN-810 (36 mg); Placebo
    PhasePhase 3
    Registry statusCompleted

  • Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

    NCT01431326 · start 2011-11

    Registered record
    Registry ID
    NCT01431326
    Conditions
    Adenovirus; Anesthesia; Anxiety; Anxiolysis; Autism; Autistic Disorder; Bacterial Meningitis; Bacterial Septicemia; Benzodiazepine; Bipolar Disorder; Bone and Joint Infections; Central Nervous System Infections; Convulsions; Cytomegalovirus Retinitis; Early-onset Schizophrenia Spectrum Disorders; Epilepsy; General Anesthesia; Gynecologic Infections; Herpes Simplex Virus; Infantile Hemangioma; Infection; Inflammation; Inflammatory Conditions; Intra-abdominal Infections; Lower Respiratory Tract Infections; Migraines; Pain; Pneumonia; Schizophrenia; Sedation; Seizures; Skeletal Muscle Spasms; Skin and Skin-structure Infections; Treatment-resistant Schizophrenia; Urinary Tract Infections; Withdrawal; Sepsis; Gram-negative Infection; Bradycardia; Cardiac Arrest; Cardiac Arrhythmia; Staphylococcal Infections; Nosocomial Pneumonia; Neuromuscular Blockade; Methicillin Resistant Staphylococcus Aureus; Endocarditis; Neutropenia; Headache; Fibrinolytic Bleeding; Pulmonary Arterial Hypertension; C
    Interventions
    The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-11
    Completion
    2019-11
    Enrolment
    3,520

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenovirus; Anesthesia; Anxiety; Anxiolysis +47 more
    InterventionThe POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
    PhaseNot recorded
    Registry statusCompleted

  • Open-Label, Extension Study to 810P202

    NCT01416064 · start 2011-09

    Registered record
    Registry ID
    NCT01416064
    Conditions
    Impulsive Aggression Comorbid With ADHD in Children
    Interventions
    Molindone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-09
    Completion
    2013-02
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionImpulsive Aggression Comorbid With ADHD in Children
    InterventionMolindone
    PhasePhase 2
    Registry statusCompleted

  • Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems

    NCT00626236 · start 2008-10-21

    Registered record
    Registry ID
    NCT00626236
    Conditions
    Attention Deficit Disorder With Hyperactivity; Conduct Disorder
    Interventions
    SPN-810; SPN-810; SPN-810; SPN-810
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-10-21
    Completion
    2009-09-23
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAttention Deficit Disorder With Hyperactivity; Conduct Disorder
    InterventionSPN-810; SPN-810; SPN-810; SPN-810
    PhasePhase 2
    Registry statusCompleted

  • Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)

    NCT00053703 · start 2002-02

    Registered record
    Registry ID
    NCT00053703
    Conditions
    Schizophrenia
    Interventions
    Risperidone; Olanzapine (enrollment closed in this treatment); Molindone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-02
    Completion
    2007-05
    Enrolment
    116

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionRisperidone; Olanzapine (enrollment closed in this treatment); Molindone
    PhasePhase 4
    Registry statusCompleted